These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 20091415)

  • 1. Structural requirement for the agonist activity of the TLR2 ligand Pam2Cys.
    Zeng W; Eriksson E; Chua B; Grollo L; Jackson DC
    Amino Acids; 2010 Jul; 39(2):471-80. PubMed ID: 20091415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Evaluation of Novel TLR2 Agonists as Potential Adjuvants for Cancer Vaccines.
    Lu BL; Williams GM; Verdon DJ; Dunbar PR; Brimble MA
    J Med Chem; 2020 Mar; 63(5):2282-2291. PubMed ID: 31418565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of
    Zhou Y; Banday AH; Hruby VJ; Cai M
    Molecules; 2019 Sep; 24(19):. PubMed ID: 31569697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptor 6-independent signaling by diacylated lipopeptides.
    Buwitt-Beckmann U; Heine H; Wiesmüller KH; Jung G; Brock R; Akira S; Ulmer AJ
    Eur J Immunol; 2005 Jan; 35(1):282-9. PubMed ID: 15580661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunostimulants and Toll-like receptor ligands obtained by screening combinatorial lipopeptide collections.
    Reutter F; Jung G; Baier W; Treyer B; Bessler WG; Wiesmüller KH
    J Pept Res; 2005 Mar; 65(3):375-83. PubMed ID: 15787968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-tetradecylcarbamyl lipopeptides as novel agonists for Toll-like receptor 2.
    Willems MM; Zom GG; Khan S; Meeuwenoord N; Melief CJ; van der Stelt M; Overkleeft HS; Codée JD; van der Marel GA; Ossendorp F; Filippov DV
    J Med Chem; 2014 Aug; 57(15):6873-8. PubMed ID: 25019313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic lipopeptide adjuvants and Toll-like receptor 2--structure-activity relationships.
    Spohn R; Buwitt-Beckmann U; Brock R; Jung G; Ulmer AJ; Wiesmüller KH
    Vaccine; 2004 Jun; 22(19):2494-9. PubMed ID: 15193414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simple synthetic toll-like receptor 2 ligands.
    Abdel-Aal AB; Al-Isae K; Zaman M; Toth I
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5863-5. PubMed ID: 21855334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells.
    Khan S; Weterings JJ; Britten CM; de Jong AR; Graafland D; Melief CJ; van der Burg SH; van der Marel G; Overkleeft HS; Filippov DV; Ossendorp F
    Mol Immunol; 2009 Mar; 46(6):1084-91. PubMed ID: 19027958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens.
    Prajeeth CK; Jirmo AC; Krishnaswamy JK; Ebensen T; Guzman CA; Weiss S; Constabel H; Schmidt RE; Behrens GM
    Eur J Immunol; 2010 May; 40(5):1272-83. PubMed ID: 20213735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel glycolipid TLR2 ligands of the type Pam2Cys-α-Gal: synthesis and biological properties.
    Thomann JS; Monneaux F; Creusat G; Spanedda MV; Heurtault B; Habermacher C; Schuber F; Bourel-Bonnet L; Frisch B
    Eur J Med Chem; 2012 May; 51():174-83. PubMed ID: 22483966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping the pulmonary environment of animals protected from virulent H1N1 influenza infection using the TLR-2 agonist Pam₂Cys.
    Mifsud EJ; Tan AC; Reading PC; Jackson DC
    Immunol Cell Biol; 2016 Feb; 94(2):169-76. PubMed ID: 26272554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccines.
    Chua BY; Zeng W; Jackson DC
    Methods Mol Biol; 2008; 494():247-61. PubMed ID: 18726578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of lipopeptide-based immunocontraceptive vaccines containing different lipid groups.
    Chua BY; Zeng W; Lau YF; Jackson DC
    Vaccine; 2007 Jan; 25(1):92-101. PubMed ID: 17055123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer.
    Kang JY; Nan X; Jin MS; Youn SJ; Ryu YH; Mah S; Han SH; Lee H; Paik SG; Lee JO
    Immunity; 2009 Dec; 31(6):873-84. PubMed ID: 19931471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Lipopeptides as Toll-like Receptor 2 Ligands.
    Hussein WM; Choi PM; Zhang C; Su M; Sierecki E; Johnston W; Fagan V; Alexandrov K; Skwarczynski M; Gambin Y; Toth I; Simerska P
    Curr Drug Deliv; 2017; 14(7):935-943. PubMed ID: 27494158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipolanthionine peptides act as inhibitors of TLR2-mediated IL-8 secretion. Synthesis and structure-activity relationships.
    Seyberth T; Voss S; Brock R; Wiesmüller KH; Jung G
    J Med Chem; 2006 Mar; 49(5):1754-65. PubMed ID: 16509590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationships in human Toll-like receptor 2-specific monoacyl lipopeptides.
    Salunke DB; Shukla NM; Yoo E; Crall BM; Balakrishna R; Malladi SS; David SA
    J Med Chem; 2012 Apr; 55(7):3353-63. PubMed ID: 22385476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route.
    Lombardi V; Van Overtvelt L; Horiot S; Moussu H; Chabre H; Louise A; Balazuc AM; Mascarell L; Moingeon P
    Clin Exp Allergy; 2008 Nov; 38(11):1819-29. PubMed ID: 18644025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-like receptor-2 agonist functionalized biopolymer for mucosal vaccination.
    Heuking S; Iannitelli A; Di Stefano A; Borchard G
    Int J Pharm; 2009 Nov; 381(2):97-105. PubMed ID: 19782879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.